Nutex Health Inc.: Form 10-Q for the period ended Mar 31, 2021
Filed with the SEC on May 24, 2021 and accepted by EDGAR at May 24, 2021, 17:25 ET.
Management's discussion and analysis
As filed, 15,705 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
FORWARD LOOKING STATEMENTS
This Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference in this Form 10-Q which address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), finding suitable merger or acquisition candidates, expansion and growth of the Company’s business and operations, and other such matters are forward-looking statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.
Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Factors that could adversely affect actual results and performance include, among others, potential fluctuations in quarterly operating results and expenses, government regulation, technology change and competition. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.
Overview
The Company, together with our recent acquisitions of AHP Management, Inc. (“AHP”) and Accountable Healthcare America, Inc. (“AHA”) is a technology-enabled, risk-bearing population health management company that manages provider networks.
Headquartered in Fort Lauderdale, Florida, our subsidiaries include management services organizations (“MSOs”), affiliated independent practice associations (“IPAs”), and Clinigence Health, Inc., a healthcare information technology company providing a cloud-based platform that enables healthcare organizations to provide value-based care and population health management (PHM). AHP Management, Inc. (AHP) is the administrative and managerial services company for its affiliated variable interest entity (VIE), a physician-owned professional corporation that contracts with independent physicians to deliver medical services in-office and virtually under the Associated Hispanic Physicians of Southern California, Inc., a Professional Medical Corporation (“AHPIPA”). Based in Los Angeles, California, AHPIPA currently provides care for 22,065 patients, including approximately 1800 Medicare Advantage patients, through a network of 141 primary care physicians and 660 specialists. AHA currently has an investment in Accountable Care Medical Group of Florida, an accountable care organizations (“ACO”), with approximately 16,000 Medicare members through a network of over 65 providers.
Recent Developments
Merger with AHP Management Inc.
On February 25, 2021, the Company, AHP, Inc., a California corporation (“AHP”), AHP Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub”), and Robert Chan (the “Shareholders’ Representative”) entered into an agreement and plan of merger (the “AHP Merger Agreement”). The transactions contemplated by the AHP Merger Agreement were consummated on February 26, 2021 (the “AHP Closing”).
The AHP Merger Agreement provided for the merger of Merger Sub with and into AHP, hereafter referred to as the “AHP Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and AHP became the surviving corporation and a direct wholly owned subsidiary of Clinigence, and the former stockholders of AHP (the “AHP Stockholders”) have a direct equity ownership in Clinigence. Merger Sub was renamed AHP Management Inc. Merger Sub was originally incorporated in Delaware on January 26, 2021 and had no operating activity prior to the reported transaction.
Merger with Accountable Healthcare America, Inc.
On February 25, 2021, Clinigence Holdings, Inc., a Delaware corporation (“Parent” or the “Company”), Accountable Healthcare America, Inc., a Delaware corporation (“AHA”), and AHA Acquisition Corp., a Delaware corporation, a wholly owned subsidiary of Parent (“Merger Sub entered into an agreement and plan of merger (the “AHA Merger Agreement”). The transactions contemplated by the AHA Merger Agreement were consummated on February 26, 2021 (the “AHA Closing”).
The AHA Merger Agreement provided for the merger of Merger Sub with and into AHA, hereafter referred to as the “AHA Acquisition.” As a result of the Acquisition, Merger Sub ceased to exist, and AHA became the surviving corporation and a direct wholly owned subsidiary of Clinigence, and the former stockholders of AHA (the “AHA Stockholders”) have a direct equity ownership in Clinigence. Merger Sub was renamed Accountable Healthcare America, Inc. Merger Sub was originally incorporated in Delaware on January 2, 2020 and had no operating activity prior to the reported transaction.
Key Financial Measures and Indicators
Operating Revenues
Our revenue primarily consists of capitation revenue and SaaS subscription services. The form of billing and related risk of collection for such services may vary by type of revenue and the customer.
Operating Expenses
Our largest expense is the patient care cost paid to contracted physicians, and the cost of providing management and administrative support services to our affiliated physician groups. These services include providing utilization and case management, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and other consulting services.
Results of operation for the three months ended March 31, 2021 as compared to the three Months ended March 31, 2020.
CLINIGENCE HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31,
(UNAUDITED)
| 2021 | 2020 | $ Change | % Change | |
|---|---|---|---|---|
| Capitation revenue | $1,594,712 | $1,594,712 | 100.00% | |
| SaaS Revenue | 419,633 | 465,630 | (45,997) | -9.88% |
| 2,014,345 | 465,630 | 1,548,715 | 332.61% | |
| Cost of sales | 1,587,473 | 199,128 | 1,388,345 | * |
| Gross profit | 426,872 | 266,502 | 160,370 | 60.18% |
| Operating expenses | ||||
| Research and development | 76,720 | 114,879 | (38,159) | -33.22% |
| Sales and marketing | 9,739 | 121,180 | (111,441) | -91.96% |
| General and administrative expenses | 573,655 | (12,726) | 586,381 | * |
| Stock based compensation | 3,852,637 | 848,778 | 3,003,859 | 100.00% |
| Amortization | 64,044 | 134,306 | (70,262) | -52.31% |
| Total operating expenses | 4,576,795 | 1,206,417 | 3,370,378 | 279.37% |
| Loss from operations | (4,149,923) | (939,915) | (3,210,008) | 341.52% |
| Other income (expenses) | ||||
| Interest income | 114 | — | 114 | 100.00% |
| Interest expense | (334,331) | (64,993) | (269,338) | 414.41% |
| Total other income (expenses) | (334,217) | (64,993) | (269,224) | 269,224 |
| Loss from continuing operations | (4,484,140) | (1,004,908) | (3,479,232) | 3,479,232 |
| Loss from discontinued operations (including gain on disposal | ||||
| of $142,027 for the three months ended March 31, 2020) | — | (117,822) | 117,822 | -100.00% |
| Net loss | (4,484,140) | (1,122,730) | (3,361,410) | 299.40% |
| Net loss attributable to noncontrolling interest | (39,581) | — | (39,581) | 100.00% |
| Net loss attributable to Clinigence Holdings, Inc. | $(4,444,559) | $(1,122,730) | $(3,321,829) | 295.87% |
| *Percentage change of over 500% |
26
Revenue
Our revenue for the three months ended March 31, 2021, was $2 million, as compared to $465,6305 for the three months ended March 31, 2020, an increase of $1.5 million, or 333%. The increase was primarily attributable to the AHP acquisition.
Cost of Services
Expenses related to cost of services for the three months ended March 31, 2021, were $1.587 million, as compared to $199,128 for the same period in 2020, an increase of $1.388 million, or 697%. The overall increase was primarily due to the AHP acquisition.
Sales and Marketing
Sales and Marketing expense for the three months ended March 31, 2021 was $9,739, compared to $121,180 for the three months ended March 31, 2020, a decrease of $ 111,441, or 92%. The decrease was primarily attributable to the reduction of sales and marketing personnel for our Clinigence Health subsidiary.
Research and Development
Research and Development expense for the three months ended March 31, 2021 was $79,720 compared to $114,879 for the three months ended March 31, 2020. The decrease was primarily attributable to the reduction of research and development personnel for our Clinigence Health subsidiary.
General and Administrative Expenses
General and administrative expenses for the three months ended March 31, 2021, were $4.4 million, as compared to $836,052 for the same period in 2020, an increase of $3.37 million, or 279%. The increase was primarily attributable to stock-based compensation expense of $3.9 million and the AHP and AHA acquisitions.
Depreciation and Amortization
Depreciation and amortization expenses for the three months ended March 31, 2021 were $64,044 as compared to $134,306 for the same period in 2020. This amount includes the amortization of intangible assets acquired from AHP and AHA.
Interest Expense
Interest expense for the three months ended March 31, 2021, was $334,331 as compared to $64,993 for the same period in 2020, an increase of $269,338 or 414%. The Interest expense reflected was primarily for interest incurred on convertible debt related to the acquisition of AHA.
Interest Income
Interest income for the three months ended March 31, 2021, was $114 as compared to $0 for the three months ended March 31, 2020. Interest income reflects interest earned on cash held in deposit accounts.
Loss from Discontinued Operations
Loss from discontinued operations was $117,822 for the for the three months ended March 31, 2020 as a result of the sale of subsidiary.
Net Income (Loss) Attributable to Noncontrolling Interests
Net Loss attributable to noncontrolling interests was $39,581 for the three months ended March 31, 2021. The was primarily due to amortization expense on intangibles in the current period allocated to the noncontrolling interest in the AHP VIE.
LIQUIDITY AND CAPITAL RESOURCES
General
We had cash of $ 3,741,458 for the three months ended March 31, 2021 compared to $ 26,931 as of December 31, 2020, an increase of $3,687,527 or 99%.
Historically, we have had a working capital deficiency and we have operated at a net loss since inception. With the acquisition of AHP we generate cash primarily from capitation contracts. In order to execute our business plans, including the expansion of operations, our primary capital requirements in 2021 are likely to rise. It is not possible to quantify those costs at this point in time, in that they depend on AHP, AHAs and Clinigence Health’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank. We believe we have sufficient liquidity to fund our operations through at least the next 12 months.
Cash Flow Activity
Cash used in operating activities for the three months ended March 31, 2021, was $567,063, as compared to cash used in operating activities of $872,992 for the three months ended March 31, 2020. The decrease in cash used in operating activities was primarily driven by an increase in revenue of $1.5 million for the three months ended March 31, 2021 as compared to the same period in the prior year, offset by $3.9 million in stock-based compensation expense.
Cash provided by investing activities during the three months ended March 31, 2021, was $3.9 million, primarily due to cash acquired in the acquisition of AHP, compared to cash used in investing activities of $2,656 from discontinued investing activities, during the three months ended March 31, 2020.
Cash provided by financing activities for the three months ending March 31, 2021 was $393,323 compared to cash used in investing activities of $22,047 for the three months ending March 31, 2020 and consisted of proceeds from notes payable of $410,088 offset by payments on notes payable of $16,765.
Plan of Operation and Funding
We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are anticipated to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock that may have a greater dilutive impact to our current shareholders. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.
The notes accompanying our financial statements for the three months ending March 31, 2021 contain an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared “assuming that the Company will continue as a going concern.” Our ability to continue as a going concern is dependent on raising additional capital to fund our operations and ultimately on generating future profitable operations. There can be no assurance that we will be able to raise sufficient additional capital or eventually have positive cash flow from operations to address all of our cash flow needs. If we are not able to find alternative sources of cash or generate positive cash flow from operations, our business and shareholders may be materially and adversely affected.
Controls and procedures
As filed, 1,997 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of March 31, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of March 31, 2021, to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under Exchange Act) during our first fiscal quarter of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Risk factors
As filed, 1,979 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on April 2, 2021. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows, or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.
These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company’s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.
Our operations and financial results are subject to various risks and uncertainties, including but not limited to those described below, which could harm our business, reputation, financial condition, and operating results.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-03-31 | $2.0m | us-gaap:Revenues |
| Cost of revenue | 3 months2021-01-01 to 2021-03-31 | $1.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2021-01-01 to 2021-03-31 | $426.9k | us-gaap:GrossProfit |
| Research and development | 3 months2021-01-01 to 2021-03-31 | $76.7k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-01-01 to 2021-03-31 | −$4.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-01-01 to 2021-03-31 | $334.3k | us-gaap:InterestExpense |
| Net income | 3 months2021-01-01 to 2021-03-31 | −$4.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-01-01 to 2021-03-31 | −$0.24 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2021-01-01 to 2021-03-31 | −$567.1k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-03-31 | $3.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-03-31 | $4.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-03-31 | $75.9m | us-gaap:Assets |
| Current liabilities | At period end2021-03-31 | $6.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-03-31 | $9.7m | us-gaap:Liabilities |
| Long-term debt | At period end2021-03-31 | $0 | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2021-03-31 | $66.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001607062-21-000142. Last ingested by Listed: Nov 14, 2026, 12:46 ET. Listed shows no prices and gives no investment advice.